Challenges of maintaining research protocol fidelity in a clinical care setting: A qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Lawton, Julia ^a   Jenkins, Nicholas ^a   Darbyshire, Julie L ^b   Holman, Rury R ^b   Farmer, Andrew J ^c   Hallowell, Nina ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN ASPART; INSULIN DETEMIR;

ADJUSTMENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMPREHENSION; CONSULTATION; CONTROLLED STUDY; DRUG SAFETY; FEEDBACK SYSTEM; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INDIVIDUALIZATION; INTERVIEW; MALE; MOTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICIPANT OBSERVATION; PROFESSIONAL PRACTICE; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STAFF; UNITED KINGDOM; AGED; ATTITUDE TO HEALTH; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE CALCULATION; HEALTH PERSONNEL ATTITUDE; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; TREATMENT OUTCOME;

AGED; ATTITUDE OF HEALTH PERSONNEL; BIOLOGICAL MARKERS; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; DRUG DOSAGE CALCULATIONS; FEMALE; GREAT BRITAIN; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; QUALITATIVE RESEARCH; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 79955507541     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-108     Document Type: Article

References (43)

1. UK Prospective Diabetes Study Group UKPDS: 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995, 45:1249-1258. UK Prospective Diabetes Study Group.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Eng J Med 2008, 359:1577-89.
3. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BE, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298. 10.1007/s00125-009-1470-0, 19655124.
4. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul SK, Levy JC. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716-30. 10.1056/NEJMoa075392, 17890232.
5. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009, 361:1736-47. 10.1056/NEJMoa0905479, 19850703.
6. International Diabetes Federation Global Guideline for Type 2 Diabetes. 2005, Brussels: International Diabetes Federation, International Diabetes Federation., http://www.idf.org
7. Lebovitz HE, Austin MM, Blonde L, Davidson JA, Del Prato S, Gavin JR, Handelsman Y, Jellinger PS, Levy P, Riddle MC, Roberts VL, Siminerio LM. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006, 12(Suppl 1):6-12.
8. Holman RR, Turner RC. A practical guide to basal and prandial insulin therapy. Diabetic Medicine 1985, 2:45-53. 10.1111/j.1464-5491.1985.tb00592.x, 2951066.
9. Hollander P, Cooper J, Bregnhøj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008, 30:1976-87. 10.1016/j.clinthera.2008.11.001, 19108786.
10. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-17. 10.1016/0168-8227(95)01064-K, 7587918.
11. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-53. UK Prospective Diabetes Study (UKPDS) Group.
12. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086. 10.2337/diacare.26.11.3080, 14578243.
13. Gough S, Frandsen AD, Toft AD. Failure of insulin monotherapy in patients with type 2 diabetes: a population-based study. Diabetes 2006, 55(Suppl 1). A109 (457-P).
14. Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among US adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008, 31:102-104.
15. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Mathhews DR, Landgraf R, Kleinebreil L. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005, 28:2673-2679. 10.2337/diacare.28.11.2673, 16249538.
16. Cefalu WT, Mathieu C, Davidson J, Freemantle N, Gough S, Canovatchel W. Patients' perceptions of subcutaneous insulin in the OPTIMISE study: A multicenter follow-up study. Diabetes Technol Ther 2008, 10:25-37. 10.1089/dia.2008.0249, 18275360.
17. Polonsky WH, Fischer L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005, 28:2543-5. 10.2337/diacare.28.10.2543, 16186296.
18. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy: The basis of patient reluctance. Diabetes Care 1997, 20:292-298. 10.2337/diacare.20.3.292, 9051375.
19. Featherstone K, Donovan JL. "Why don't they just tell me straight, why allocate it?" The struggle to make sense of participating in a randomised controlled trial. Soc Sci Med 2002, 55:709-19. 10.1016/S0277-9536(01)00197-6, 12190265.
20. Lowton K. Trials and tribulations: understanding motivations for clinical research participation amongst adults with cystic fibrosis. Soc Sci Med 2005, 61(8):1854-65. 10.1016/j.socscimed.2005.03.039, 15913858.
21. Lawton J, Fox A, Fox C, Kinmonth AL. Participating in the United Kingdom Prospective Diabetes Study (UKPDS): a qualitative study of patients' experiences. Br J Gen Pract 2003, 53:394-8. 1314601, 12830569.
22. Canvin K, Jacoby A. Duty, desire or indifference? A qualitative study of patient decisions about recruitment to an epilepsy treatment trial. Trials 2006, 12:32.
23. Snowdon C, Garcia J, Elbourne D. Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. Soc Sci Med 1997, 45:1337-55. 10.1016/S0277-9536(97)00063-4, 9351153.
24. Madsen SM, Holm S, Riis P. Attitudes towards clinical research among cancer trial participants and non-participants: an interview study using a Grounded Theory approach. J Med Ethics 2007, 33:234-40. 10.1136/jme.2005.015255, 2652783, 17400624.
25. Ziebland S, Featherstone K, Snowdon C, Barker K, Frost H, Fairbank J. Does it matter if clinicians recruiting for a trial don't understand what the trial is really about? Qualitative study of surgeons' experiences of participation in a pragmatic multi-centre RCT. Trials 2007, 27:4.
26. Kenyon S, Dixon-Woods M, Jackson CJ, Windridge K, Pitchforth E. Participating in a trial in a critical situation: a qualitative study in pregnancy. Qual Saf Health Care 2006, 15:98-101. 10.1136/qshc.2005.015636, 2464828, 16585108.
27. Pope C, Mays N. Qualitative research: reaching the parts other methods cannot reach: an introduction to qualitative methods in health and health services research. BMJ 1995, 311:42-5. 2550091, 7613329.
28. Strauss A, Corbin J. Basics of qualitative research: grounded theory procedures and techniques. 1990, London: Sage.
29. Glaser B, Strauss A. The Discovery of Grounded Theory. 1967, Chicago: Aldine.
30. Jenkins N, Hallowell N, Farmer AJ, Holman RR, Lawton J. Initiating insulin as part of the Treating to Target in Type 2 Diabetes (4-T) trial: An interview study of patients' and health professionals' experiences. Diabetes Care 2010, 33:2178-2180. 10.2337/dc10-0494, 20592050.
31. Lutfey K. On practices of 'good doctoring': reconsidering the relationship between provider roles and patient adherence. Sociol Health Illn 2005, 27:421-47. 10.1111/j.1467-9566.2005.00450.x, 15998345.
32. Wood F, Prior L, Gray J. Translations of risk: decision making in a cancer genetics clinic. Health, Risk and Society 2003, 5:185-198.
33. Ruston A. Interpreting and managing risk in a machine bureaucracy: professional decision-making in NHS direct. Health, Risk & Society 2006, 8:257-271. 10.1080/13698570600871729, 21547917.
34. Timmermans S, Berg M. The Gold Standard: The Challenge of Evidence-Based Medicine and Standardization in Health Care. 2003, Philadelphia: Temple University Press.
35. Hallowell N, Cooke S, Crawford G, Parker M, Lucassen A. Health Professionals' and researchers' understanding of cancer genetics activities: a qualitative interview study. J Med Ethics 2009, 35:113-119. 10.1136/jme.2008.024224, 19181885.
36. Miller FA, Giacomini M, Ahem C, Robert JS, de Laat S. When research seems like clinical care: a qualitative study of the communication of individual cancer genetics research results. BMC Med Ethics 2008, 9:4. 10.1186/1472-6939-9-4, 2267198, 18294373.
37. Lehman R, Krumholz H. Tight control of blood glucose in long standing type 2 diabetes. BMJ 2009, 338:901-902.
38. MRC A Framework for the development and evaluation of RCTs for complex interventions to improve health. 2000, 1-19. London Medical Research Council, Issue: 27/02/05, MRC.
39. Joffe S, Weeks JC. Views of American oncologists about the purposes of clinical trials. J Nat Cancer Inst 2002, 94:1847-53.
40. Gurses AP, Seidl KL, Vaidya V, Bochicchio G, Harris AD, Hebden J, Xiao Y. Systems ambiguity and guideline compliance: a qualitative study of how intensive care units follow evidence-based guidelines to reduce healthcare-associated infections. Qual Saf Health Care 2008, 17:351-359. 10.1136/qshc.2006.021709, 18842974.
41. Kinmonth AL, Wareham NJ, Hardeman W, Sutton S, Prevost AT, Fanshawe T, Williams KM, Ekelund U, Spiegelhalter D, Griffin SJ. Efficacy of a theory-based behavioural intervention to increase physical activity in an at-risk group in primary care (ProActive UK): a randomised trial. Lancet 2008, 371(9606):41-8. 10.1016/S0140-6736(08)60070-7, 18177774.
42. Farmer AJ, Wade A, French D, Goyder E, Kinmonth A, Neil HAW. The DiGEM trial protocol - a randomised controlled trial to determine the effect on glycaemic control of different strategies of blood glucose self-monitoring in people with type 2 diabetes. BMC Family Practice 2005, 6:25. 10.1186/1471-2296-6-25, 1185530, 15960852.
43. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F. Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 2002, 325:766-70. 10.1136/bmj.325.7367.766, 1124277, 12364308.